Back Home

Maximizing Immunoassay Performance

Maximizing Immunoassay Performance

  • HOME
  • ABOUT US
    • Founders
    • Why InfYnity
    • Who we are
    • What we do
  • OFFER
    • Biomaterial Products
    • Biomaterial Design
    • Immunoassay RUO products
    • Immunoassay Development Services
    • Multiplex Services
  • CONTACT US
    • Careers
  • Pipeline
  • Partners
Home » 2021 » April » 07

News

  • Lancet Infectious Disease publication on an innovative multiplex test for forecasting parasitological cure in Chagas patients
  • InfYnity Multiplex ELISA Platform: Reliable & Highly Reproducible
  • MEDICA (November 18-21, 2019)
  • HERVS & Disease (November 5-6, 2019)
  • Chagas Disease Monitoring: Time for analysis of serological patterns
  • NIH Award to develop a Test-of-Cure for Chagas disease
  • Stars of Science – Session 10 (2018)
  • Chagas Platform Meeting (November 14-15, 2018)
  • MEDICA (November 12-15, 2018)
  • Biotuesday (September 4, 2018)

Daily Archives: April 7, 2021


Chagas disease, caused by the parasite Trypanosoma cruzi, is a major neglected tropical disease in Latin America affecting over 6 million people. A test-of-cure to monitor treatment efficacy is desperately needed. Using a novel multiplex immunoassay Multi-Cruzi, and in combination with a mathematical formula, InfYnity Biomarkers (France), DNDi, and the […]

Lancet Infectious Disease publication on an innovative multiplex test for ...

7 Apr, 2021  in Biotechnology by Lola MARQUE


INFYNITY BIOMARKERS

78-80 rue du Bourbonnais
69009 Lyon – France

Tel: +33 4 72 76 20 29
Fax: +33 9 81 38 17 15
Email: info@infynity-biomarkers.com

Map: https://map.what3words.com/portique.retrouvons.sportif

Mentions Légales

 

· © 2021 infYnity-biomarkers ·

Web Design MymensinghPremium WordPress ThemesWeb Development